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1. Introduction 
Approximately 50 years ago, pharmacogenetics emerged as a new field of medicine that 
may explain human drug action. Anesthesia, in particular, played a key role in these early 
investigations. An understanding of how an individual’s genetic footprint influences drug 
metabolism and effectiveness may allow tailored prescriptions, improving outcomes and 
safety; and such concepts, which form the backbone of personalized medicine, have raised a 
lot of hope. The ultimate goal of pharmacogenetics research is to offer ‘tailored personalized 
medicine’ with a view to improving the efficacy of medication as well as patient safety by 
helping predict risks of adverse outcomes.  
In this Chapter, we first present a selection of historical landmarks related to anesthesia as a 
catalyst for the development of pharmacogenetics, we then cite practical examples of 
relevant candidates genes and common polymorphisms that are known to alter the response 
to medication prescribed in the perioperative and peripartum period as well as clinical 
outcomes in the parturient. To conclude, we hope to present current views and potential 
exciting perspectives that may arise from the application of pharmacogenetics to the daily 
practice of obstetric anesthesia and pain medicine.  
2. The history of pharmacogenetics related to anesthesia 
Medical genetics began with the 20th century rediscovery of Gregor Mendel’s original 19th 
century work on plant genetics 1. In 1949, the landmark paper in Science by Linus Pauling 
and colleagues linked sickle cell anemia to a derangement in a specific protein 2, and was the 
first proof that a genetic change alters the structure and function of a protein and results in a 
human disease. This set the stage for the birth of pharmacogenetics, a field first described by 
Arno Motulsky in 1957 3, named by Friedrich Vogel in 1959 4, and established by Werner 
Kalow in 1962 5. These scientists defined pharmacogenetics as the study of the variability in 
drug response due to genetic variability. In the early 1950s, prolonged apnea after 
succinylcholine was one of the drug responses that provided a starting point from which the 
new field of pharmacogenetics would launch. In 1956, The Lancet published a paper that was 
the first to suggest a genetic basis for prolonged apnea after succinylcholine 6. Werner 
Kalow reported soon after the occurrence of prolonged postoperative muscle relaxation 
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following the administration of succinylcholine for endotracheal intubation, and described 
how an inherited variation of drug metabolism involving the enzyme butyrylcholinesterase 
affects the response to succinylcholine 7. Malignant hyperthermia after succinylcholine or 
inhaled volatile anaesthetics is another example of an adverse reaction important to the 
history of pharmacogenetics. To date, 30 causative mutations have been identified on the 
ryanodine receptor gene (RYR1) that are associated with malignant hyperthermia 8,9. 
Guidelines proposed by the European Malignant Hyperthermia Group were the first to 
describe comprehensive genetic screening for a pharmacogenetic test in the field of 
anesthesia 10.  
3. The pharmacogenetics research network 
Since the first reports ten years ago describing initial findings from the Human Genome 
Project 11,12, and its completion in 2003 13, promises that these discoveries would translate 
into tangible clinical tests that may change drug prescriptions have been somewhat 
unfulfilled. Working towards this translation, the pharmacogenetics research network has 
established a pharmacogenomics knowledge base (PharmGKB) with the goal to collect, 
encode, and disseminate knowledge about the impact of human genetic variations on drug 
response, curate primary genotype and phenotype data, annotate gene variants and gene-
drug-disease relationships via literature review, and summarize important pharmacogenetic 
genes and drug pathways (http://www.pharmgkb.org) (Figure 1).  
 
 
Fig. 1. Pharmacogenomics (PGx) information flow 
Adapted from the NIH Pharmacogenomics Research Network – Pharmacogenomics 
Knowledge Base (http://www.pharmgkb.org) 
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4. The relevance for obstetric anesthesia and analgesia 
Numerous clinical trials and reviews have surfaced in recent years describing genetic 
associations with clinical outcomes in the field of anesthesia, peri-operative outcomes and 
pain medicine 14-28. An overview of all the drugs utilized in the peri-operative and 
peripartum period is beyond the scope of this review. For this Chapter, we selected several 
clinical examples for which gentoype/phenotype effects have been evaluated and present 
their relevance for clinical practice.  
4.1 The 2-adrenergic receptor genotype  
Several single nucleotide polymorphisms (SNPs) that have been described in the gene 
encoding the human 2-adrenergic receptor (2AR) affect the function of the receptor in vitro. 
Substitution of glycine for arginine at position 16 (Arg16Gly) has been associated with 
enhanced agonist-induced desensitization, while substitution of glutamic acid for glutamine 
at position 27 (Gln27Glu) has been associated with resistance to desensitization 29. 
Significant differences in the response of individuals to 2AR therapeutic manipulation 
related to the particular genotype/haplotype of the 2AR have been demonstrated. The 
2AR is of particular interest for obstetric anesthesia, since drugs that are given to ensure 
hemodynamic stability at the time of delivery, as well as drugs to promote uterine 
quiescence (tocolysis) act via 2-agonism. 
4.1.1 Vasopressor requirement during spinal anesthesia for Cesarean delivery 
Numerous clinical trials have evaluated the response to vasopressors to prevent and or treat 
hypotension during spinal anesthesia for elective Cesarean delivery 30. For decades, 
ephedrine has been considered the safest and probably the sole acceptable strategy, based 
on classic studies in sheep that suggested deleterious effects of pure -adrenergic agonists 
on uteroplacental blood flow. Ephedrine has been widely used in a variety of regimens 
(different bolus doses, infusions and in combination with phenylephrine) although no 
consensus has ever been achieved as to which of these modes of administration provides the 
most reliable and effective response. Ephedrine is a sympathomimetic amine, the principal 
mechanism of its action relies on its direct and indirect actions on the adrenergic receptor 
system (both an - and -adrenergic agonist).  
A pharmacogenetic study in an obstetric population showed that the incidence and severity 
of maternal hypotension after spinal anesthesia for Cesarean delivery and the response to 
treatment is clearly affected by 2AR genotype/haplotype 31. Women Gly16 homozygous 
and carrying one or two Glu at position 27 (heterozygous or homozygous for the minor 
Glu27 allele) were found to require significantly less vasopressors (ephedrine) for treatment 
of hypotension during spinal anesthesia. The two haplotypes that seem to ‘protect’ women 
from requiring higher doses of ephedrine are relatively common in Caucasians, and in this 
study 20% of the women carried either one of these haplotypes. This pharmacogenetic effect 
may explain in part why the numerous studies trying to prevent or treat hypotension 
during spinal anesthesia for Cesarean section failed to define one single optimal strategy 
(fluid loading, ephedrine or phenylephrine) that would ‘fit all’.  
Since the incidence of spinal hypotension and vasopressor use is reduced in preeclampsia 
32,33, it has been further hypothesized that haplotypes of 2AR gene influence hemodynamics 
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during spinal anesthesia for Cesarean delivery in women diagnosed with severe pre-
eclampsia. In a prospective case-control study, we compared the incidence of hypotension 
and vasopressor requirements in a predominantly African-American cohort 34. Despite a 
trend towards fewer pre-eclamptic women requiring vasopressors, the total vasopressor 
dose was higher in those in whom treatment was indicated. However, no woman in the pre-
eclamptic group carried the Gly16Gly/Glu27Glu haplotype, and since this was one of the 
two haplotypes that predicted less vasopressor requirement in normotensive women 31, this 
might provide an explanation for these unexpected results. Whether these findings are 
specific to African-American women remains to be determined in larger studies in other 
ethnic groups. These findings illustrate the importance of ethnicity when assessing genetic 
associations, and similar interactions between ethnicity and genetics have been suggested 
for other SNPs presented in this review (-OR). In the long term, if these findings are 
confirmed, clinical implications could involve using haplotype of 2AR to predict spinal 
hypotension and to guide hemodynamic management in women with compromised 
cardiovascular function and altered uteroplacental perfusion.  
4.1.2 Ephedrine-induced neonatal acidosis 
Meanwhile, the direct effects of ephedrine on the fetus have been revisited recently 35. 
Evidence that ephedrine crosses the placenta to a greater extent and undergoes less early 
metabolism and redistribution than phenylephrine (a direct -adrenergic agonist) causing 
direct fetal metabolic acidosis has made ephedrine less desirable as a first-line treatment 36. The 
proposed mechanism is that direct fetal -adrenergic stimulation increases anaerobic 
glycolysis and causes a hypermetabolic state. The hypothesis that neonatal ADRB2 genotype 
may directly influence the degree of neonatal acidemia in response to ephedrine given to the 
mother prior to delivery has just recently been explored. The most clinically relevant and 
intriguing finding of a study conducted in Asian woemen was that umbilical artery (UA) pH 
was overall higher and UA lactate was lower in neonates that were Arg16 homozygous as 
compared to neonates with the two other genotypes of ADRB2 37. Furthermore, among babies 
born to mothers receiving ephedrine, ephedrine dose was associated with neonatal acidemia 
(decreased UA pH) only in neonates carrying a Gly16 allele, but not in neonates who were 
Arg16 homozygous. Since there was no significant difference in ephedrine concentration as 
determined by maternal and umbilical cord assays among genetic groups, any difference in 
metabolic markers are unlikely to have resulted from differential transplacental transfer of 
drug or a pharmacokinetic effect. Arg16 homozygous neonates seem to be protected from the 
risk of developing acidemia when exposed to ephedrine, irrespective of the dose given to the 
mother (Figure 2). These findings provide interesting insight on fetal acidosis and metabolic 
responses in neonates born to mothers who have received -agonists (ephedrine and/or other 
-stimulants prescribed for tocolysis or bronchodilation) prior to delivery. 
4.1.3 Tocolytics for management of preterm labor and delivery 
Stimulation of the 2AR results in uterine smooth muscle relaxation, and thus the 2AR has 
long been a therapeutic target for the treatment of preterm labor. 2-agonist therapy, in 
common with virtually all tocolytics, has not been consistently successful at stopping 
preterm labor or prolonging pregnancy, in part due to the multifactorial nature of preterm 
labor, and possibly because of a wide variability in therapeutic response within the 
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population. The mechanisms involved in regulation of myometrial smooth muscle 
contraction and relaxation in preterm labor or even at term are not yet fully elucidated. 
Genetic variability of ADRB2 has been evaluated in several studies in the context preterm 
labor and delivery. Arg16 homozygosity of ADRB2 appears to confer a protective effect 
against preterm delivery while the minor allele at position 27 (Glu) increases the risk for 
preterm delivery 38-40. Furthermore, a pharmacogenetic effect, with a better response to 
2agonist therapy (hexoprenaline) for tocolysis in women Arg16 homozygous with idiopathic 
preterm labor between 24 and 34 weeks gestation has been demonstrated 41. This had a 
significant impact on neonatal outcomes, with higher birth weights and less neonatal intensive 
care unit (NICU) admissions for respiratory or other complications due to prematurity in 
babies born to mothers with that genotype. Meanwhile, a variety of genomic studies have 
examined the influence of genetic variants on the incidence of preterm labor 42, and proteomic 
studies to validate biomarkers that could identify women at risk for preterm delivery and 
serve as predictive tools are ongoing 43,44.  
 
Fig. 2. Ephedrine-induced neonatal acidosis according to p.16Arg/Gly of ADRB2 
From Landau R, Liu SK, Blouin JL, Smiley RM, Ngan Kee WD: The Effect of Maternal and Fetal 2-
Adrenoceptor and Nitric Oxide Synthase Genotype on Vasopressor Requirement and Fetal Acid-Base 
Status During Spinal Anesthesia for Cesarean Delivery. Anesth Analg 2011; 112: 1432-7 
4.1.4 Course of labor and delivery 
Recent studies have confirmed that ADRB2 haplotype is important not only in the context of 
preterm onset of labor and delivery, but also on the course of labor and delivery in the term 
parturient. In a recent observational study in North-American women enrolled between 34-40 
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weeks gestation, the progress of active labor was found to be slower in women homozygous 
for Arg16 45. In women at term, the rate of cervical dilatation and duration of labor was shown 
to be slower in women carrying the wild-allele (Gln) at position 27 46. Taken together, both 
studies confirm that uterine quiescence during pregnancy and progression of cervical 
dilatation during labor are strongly associated with ADRB2 haplotype. 
5. Analgesia and pain-related candidate genes 
Interindividual variability in pain perception and sensitivity to analgesic therapy with a 
large unpredictability in efficacy, side effects and tolerance profiles to opioids is well 
described. Genomic and pharmacogenetic research has considered numerous candidate 
genes as suitable targets for the study of pain and or analgesia 47. Among the numerous 
genes and specific polymorphisms that have been considered important in opioid response, 
the A118G polymorphism of the opioid receptor gene (OPRM1), a common variant of the 
catechol-O-methyltransferase gene (Val158Met of COMT), several genetic variants of the 
ATP-binding cassette, sub- family B gene (ABCB1) and genetic variants of the cytochrome 
P450 family of enzymes have been extensively reviewed 22,24,48. In addition, a genetic 
database of knock-out mice allowing the study of genetic variations in the context of specific 
pain phenotypes was made public 49. 
Recently an extremely rare phenotype characterized by a total absence of pain perception 
(‘congenital indifference to pain’) with no associated neuropathy has been associated with the 
mutations in the gene SCN9A, encoding the α-subunit of the voltage-gated sodium channel, 
Nav1.7 50-52. Individuals with loss-of-function mutations of the NaV1.7 lack protective 
mechanisms that allow tissue damage detection and suffer severe injuries because they do not 
learn pain-avoiding behaviors. This discovery opens new directions for development of novel 
generations of drugs with blocking Nav1.7 proprieties, which should provide more selective 
and safe analgesia. Meanwhile, we are still in the era of opioid therapy, and the analgesic effect 
may be influenced by alterations in the metabolism of analgesic drugs (cytochrome P450), 
variants coding for the -opioid receptor (OR) as well as other targets. 
5.1 Cytochrome P450 and the codeine story 
Cytochrome P450 (CYP450) is a super-family of liver enzymes that catalyze phase 1 drug 
metabolism. The D6 isozyme of the CYP2 family is particularly affected by genetic 
variability and currently has 80 identified CYP2D6 alleles (http://www.cypalleles.ki.se/), 
resulting in a variable enzymatic activity ranging from 1 to 200%. As a result, each 
individual can be classified as having an “ultra-rapid metabolism” (UM), an “extensive 
metabolism” (EM), an “intermediate metabolism” (IM) or a “poor metabolism” (PM) and 
microarray technology is available to classify individuals according to their metabolic 
phenotype. Furthermore, it is important to note that the distribution of CYP2D6 phenotypes 
varies with race, since mutated alleles differ among racial and ethnic groups. Of note, 
approximately 7 to 10% of Caucasians have no CYP2D6 activity (poor metabolism) because 
of deletions, frameshift, or splice-site mutations of the gene. On the other end of the 
spectrum, 1 to 3% of Middle Europeans and up to 29% of Ethiopians have duplications of 
the CYP2D6 gene and are classified as ultra-rapid metabolizers 53. Ultra-rapid metabolizers 
have up to 50% higher plasma concentrations compared to extensive metabolizers 54. 
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Codeine is a pro-drug and needs to be converted into morphine to elicit its analgesic effect; 
therefore ‘poor metabolizers’ do not achieve analgesia with codeine while they may 
encounter side effects such as nausea and vomiting. Codeine is converted to morphine 
through O-demethylation catalyzed by CYP2D6, and accounts for 10% of codeine clearance. 
The conversion of codeine into norcodeine by CYP3A4 and into codeine-6-glucuronide by 
glucuronidation represents approximately 80% of codeine clearance. Morphine is further 
metabolized into morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G), and 
morphine and M6G have opioid activity. While codeine is undoubtedly not a wonder 
analgesic, it was initially prescribed because of the belief that being a weak opioid, it is safe. 
There was a recent FDA warning on codeine use in nursing mothers following the death of a 
breastfed 13-day-old neonate thought to have suffered a morphine overdose because his 
mother was taking codeine 55. Toxic blood levels of morphine or its active metabolite 
morphine-6-glucuronide (M6G) may arise in mothers and neonates that are CYP2D6 ultra-
rapid or extensive metabolizers. The infant in this case report was categorized as a CYP2D6 
extensive metabolizer (extensively metabolizing the pro-drug codeine to morphine) and had 
a blood concentration of morphine at 70ng/mL; neonates breastfed by mothers receiving 
codeine typically have concentrations of 0-2.2ng/mL. The mother was categorized as a 
CYP2D6 ultra-metabolizer and her breast milk had a morphine concentration of 87ng/mL – 
the typical range being 1.9-20.5ng/mL at doses of 60mg codeine every 6 hours. Therefore, 
the infant had two reasons for having supranormal morphine levels. In light of these 
findings, it has been suggested that codeine be avoided in breastfeeding mothers with a 
CYP2D6 extensive or ultra-rapid metabolism genotype. Reports followed that studied the 
rates of codeine and morphine clearance in breastfeeding mothers and their relation to 
CYP2D6 genotypes 56-58. Other life-threatening adverse events have been reported in 
individuals who are CYP2D6 ultra-rapid metabolizers 59,60. 
Since 2007, the FDA requires manufacturers of prescription codeine products to state in the 
“Precautions” section of the drug label the known risks of prescribing codeine to breastfeeding 
mothers 61. An FDA-approved genetic test (AmpliChip CYP450: Roche Diagnostics, Palo Alto, 
CA, USA) is commercially available to test genetic variants of CYP2D6 62. 
Overall, the level of evidence linking gene variation (CYP2D6) to phenotype (increased 
biotransformation of codeine into morphine) is strong, however there is no randomized clinical 
trial assessing the benefits of genetic testing prior to codeine therapy at large. Currently, the 
only recommendation for risk aversion is a cautionary insert to avoid codeine in breastfeeding 
mothers (or to apply genetic testing in mothers/neonates if codeine is prescribed). 
5.2 The -opioid receptor genotype 
The -opioid receptor gene (OPRM1) is probably the most well studied gene in the context 
of post-operative and labor analgesia 63. The most common polymorphism of OPRM1 is a 
single nucleotide substitution at position 118, with an adenine substitution by a guanine 
(A118G) reported to occur with an allelic frequency of 10–30% among Caucasians 64, a 
higher prevalence among Asians 65 and a lower one in African-Americans 66. Clinicians are 
well aware of the large and unpredictable inter-individual variability in response to opioids 
67. A recent meta-analysis of all pain studies evaluating the impact of A118G polymorphism 
of OPRM1 on the response to opioids did not identify a strong association between this 
polymorphism and the response to opioids 63. It is likely that the heterogeneity of the clinical 
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situations (experimental pain, acute pain, labor pain, post-operative pain, chronic pain) and 
diversity of evaluated drugs and dosages precluded from any significant findings.  
5.2.1 Response to intrathecal and systemic morphine for post-Cesarean analgesia 
The response to an intrathecal solution containing morphine and fentanyl for post-Cesarean 
analgesia according to OPRM1 genotype was evaluated in a North-American cohort 68. 
There was no difference in the duration of spinal morphine analgesia or need for analgesic 
supplementation over 72 hours in women carrying the minor allele (G118). The time for first 
opioid rescue analgesia was on average 22 hours regardless of genotype. The incidence of 
nausea was similar between groups, however pruritus was less frequent during the first 24 
hours in women carrying the minor allele (G118).  
In two studies from Singapore in women undergoing Cesarean deliveries under spinal 
anesthesia (with morphine), women with the minor allele allele exhibited increased 
consumption of iv PCA morphine 24 hours post-delivery 69,70. Women were given upon 
arrival in the post-anesthesia care unit (PACU) a morphine iv PCA pump and no other 
analgesics were prescribed. In the first study on 588 Chinese Singaporean, 24 hours post-
operative morphine iv PCA consumption was lowest in women homozygous for the wild-
type allele (A118) 69. Distribution of morphine use over time (doses were recorded in 4 
hour time intervals) demonstrated that most of morphine use occurred in the PACU 
during the first 4 hour after spinal anesthesia. It is possible that this early iv morphine use 
reflects lack of analgesia upon arrival in the PACU. Consequently, initial differences in iv 
morphine use may be due to differences in pain perception rather than impaired spinal 
morphine analgesia in women carrying the minor allele (G118), while differences of 
morphine use at 24 hour reflect either differences in intrathecal morphine duration 
and/or efficacy or more likely differences in iv morphine efficacy. The overall incidence 
of nausea was low; nonetheless it was higher in women homozygous for the wild-type 
allele (A118). 
In the second publication, 994 women from the three main ethnic groups in Singapore were 
evaluated (n=617 Chinese, n=241 Malays and n=136 Indians) 70. The authors reported a large 
inter-individual range with 65 women not using any morphine, 129 using only one dose, 
while another 122 administered 2 doses. Total iv morphine use over the first 24 hours was 
significantly higher in women homozygote for the minor allele (G118), and incidence of 
nausea was again lower in this genotypic group. In a multiple regression analysis, the most 
important factor contributing to morphine usage was maximum pain score, followed by 
ethnicity and A118G polymorphism. After correction for genotype, ethnicity was still a 
significant contributing factor, with Indian women reporting higher pain scores and using 
higher doses of iv morphine. 
This apparent discrepancy between the North-American study reporting no effect of 
OPRM1 A118G polymorphism on intrathecal morphine analgesia and the Singaporean 
results may be explained by differences in ethnicity, study design and primary outcomes. In 
the Singaporean studies, the intrathecal solution did not include fentanyl therefore it is 
possible that onset of intrathecal analgesia occurred after women arrived in the PACU. Since 
women were given iv PCA morphine as the initial rescue analgesic (rather than ibuprofen as 
in the North-American study), such study design was more likely to evaluate the effect of 
A118G polymorphism on iv morphine analgesic rather than intrathecal analgesic response. 
www.intechopen.com
 
Pharmacogenetics and Obstetric Anesthesia and Analgesia 
 
257 
Another obvious explanation may be that OPRM1 genotype interacts differently with opioid 
analgesia in different ethnic groups. 
 
Study 
Subjects 
(N) 
Study cohort 
Route of 
administration 
Measured 
outcomes 
Observed 
associations 
Landau 
(34) 
223 
Nulliparous 
women in early 
labor 
Spinal (up-down 
sequential and 
randomized doses) 
ED50 (median 
effective dose 
providing 60min 
of early labor 
analgesia) 
G118 carriers 
requested analgesia 
at later stage (greater 
cervical dilatation) 
and required less 
spinal fentanyl 
Wong 
(35) 
147 
Nulliparous 
women in early 
labor 
Spinal (25mcg) 
Duration of 
effective 
analgesia in 
early labor 
No difference in 
duration of analgesia 
between genotypes 
Fukuda 
(36) 
280 
(183 
women) 
Healthy 
Japanese, 
orodental 
surgery 
 Pre-op IV test: 
(2mcg/kg) 
 
 Post-op iv PCA 
(40mcg/10min) 
 Cold-pressor 
test   before vs 
after iv dose 
 
 24h post-op iv 
PCA 
consumption 
 Pre-iv test: 
decreased sensitivity 
in A118 
 Post-iv test: 
enhanced analgesic 
effect in A118 
 Reduced fentanyl 
sensitivity in women 
vs men 
 No difference in 
VAS scores and 24h 
post-op fentanyl 
consumption 
between genotypes 
Wu 
(37) 
189 
(97 women) 
Han Chinese, 
laparoscopic 
abdominal 
surgery 
 Pre-op IV (5mcg/kg) 
 Intra-op IV 
(1mcg/kg/30min) 
 Post-op IV 
(1mcg/kg) 
 Post-op pain 
scores (15, 30, 45, 
60min) 
 Time to 
awakening 
 Respiratory 
depression 
 PaCO2 
 
 Lower pain scores 
in A118 (at 15 and 
30min) 
 Longer time for 
awakening in A118 
 Higher PaCO2 in 
A118 subjects 
Zhang 
(38) 
174 
Han Chinese, 
hysterectomy 
 Pre-extubation 
(1mcg/kg) 
 Post-op IV PCA 
(continuous 5mcg/h 
bolus 20mcg/5min) 
 Pre-op 
electrical pain 
threshold 
 24h post-op 
VAS scores 
 24h post-op IV 
PCA 
consumption 
 No difference in 
pain threshold 
 Lower electrical 
pain tolerance 
threshold in G118 
carriers (gene-dose 
dependant effect) 
 No difference of 
initial post-op or 
averaged 24h pain 
scores 
 Higher 
consumption of post-
op fentanyl in G118 
homozygotes 
 Trend for higher 
incidence PONV in 
A118 subjects 
Table 1. Recent studies evaluating OPRM1 A118G SNP and fentanyl analgesic effect 
From Landau R, Kraft JC: Pharmacogenetics in obstetric anesthesia. Curr Opin Anaesthesiol 2010; 
23: 323-9 
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5.2.2 Response to intrathecal fentanyl for labor analgesia 
Using the up-down sequential allocation model to identify differences in analgesic 
requirement according to OPRM1 genotype in a Swiss cohort of nulliparous women 
requesting neuraxial analgesia early in labor, women carrying the minor allele  (G118) 
required substantially lower doses of intrathecal fentanyl 71. The ED50 (median effective 
dose providing labor pain relief defined on a 0-10 verbal numerical pain scale as being < 1 
for at least 60 minutes) of intrathecal fentanyl given as part of a combined-spinal epidural 
(CSE) was 1.5 fold higher in A118 homozygotes versus that in women carrying at least one 
minor allele (G118). Moreover, this finding was replicated using random-dose allocation 
(doses ranging from 2.5-35µg), with a 2.1-fold difference between genetic groups. Of note, 
cervical dilatation at the time of analgesia request was significantly less in women 
homozygote for wild-type allele (A118) than in women carrying one or two minor alleles 
(G118). This is of interest because women received the CSE analgesic when they requested 
pain relief at the time they experienced painful contractions. It has previously been 
demonstrated that epidural analgesic requirements increase with progress of labor and 
cervical dilatation, therefore women carrying the variant G118 allele should have greater 
analgesic requirements due to the greater cervical dilatation at which they requested 
analgesia; our finding that these women require less fentanyl may actually underestimate 
the true effect of genotype. Since provision of optimal labor analgesia remains an ongoing 
challenge for obstetric anesthesiologists, the variability in ED50 according to genotype is 
clearly relevant from a clinical standpoint. These findings suggest genotyping may help 
improve the administration of labor analgesia with 30% of Caucasian women (and probably 
a vast majority of Asian women) potentially requiring lower doses of intrathecal fentanyl for 
effective analgesia during labor and delivery. 
In a North-American cohort, the effect of the A118G polymorphism on the duration of 
intrathecal fentanyl analgesia in early labor and found no difference between genotypes 68. 
The severity of nausea, pruritus or incidence of vomiting was also not different between 
genetic groups. While the A118G polymorphism may influence intrathecal fentanyl potency, 
there may be no pharmacokinetic effect altering duration of analgesic action. 
Overall, the level of evidence linking gene variation to morphine or fentanyl response is 
moderate, probably due to the inherent complexity of studying pain (different nociceptive 
modalities, gender differences, limitations in extrapolating data from animal models to the 
response in humans, interethnic and environmental differences) in addition to the obvious 
polygenic nature of pain and analgesic response. The design and execution of large clinical 
studies analyzing multiple haplotypes simultaneously remains to be the true challenge to 
date. Meanwhile, a genome-wide study in the context of acute post-operative pain was 
published 21, the possible impact of epigenetics-based strategies for pain therapy is proposed 
72 and researchers are actively working on gene therapies for chronic pain 73-75. It will also be 
of interest to see the new insights and developments brought by more research on the 
SCN9A gene, a gene involved in channelopathies that result in the inability to experience 
pain, and potential targeted therapies 76. 
6. The future of personalized medicine 
Perhaps the most exciting yet challenging development of personalized medicine emerged 
with the highly sophisticated technology that now allows whole genome sequencing at a 
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cost that is no longer prohibitive. Therefore, extensive considerations are needed to decide 
how to best utilize whole genome sequencing data in clinical practice 77. Among these 
challenges, patients will need to receive complex and detailed genetic counseling before 
they can decide whether they wish to undergo such genetic risk assessment, and effective 
ways to convey meaningful information to patients about the many implications of their 
whole-genome sequences need to be developed. In addition, interpretation should take into 
account the limits of the sequencing method used. Databases with easily accessible and well 
validated information about the associations between genomic sequences and diseases 
needs to be created, maintained, and frequently updated to incorporate new information 
about disease risks, and changes in assessment will have to be communicated to patients.  
A fascinating report on the first integrated analysis of a complete human genome in the 
clinical context of a 40 year old male who presented with a family history of coronary artery 
disease and sudden death addressed these issues 78. Disease and risk analysis of the genome 
for this individual study was focused on variants associated with genes for known 
Mendelian disease, novel mutations, variants known to have a pharmacogenetic effect, and 
SNPs previously associated with complex disease. The subject was found to have an 
increased genetic risk for myocardial infarction, type II diabetes and certain cancers. With 
this report, the authors developed tools to integrate the subject’s clinical characteristics, his 
family history and the results from whole genome sequencing including 2.6 million SNPs 
and 752 copy number variations to assist clinical decision-making. Large-scale 
implementation of such sophisticated methodology will require multidisciplinary 
approaches that include medical and genetic professionals, ethicists and regulatory 
agencies.  
7. Conclusions 
There is no doubt that genetic variants affect drug responses to an extent that can have 
relevant implications beyond just the efficacy of a prescribed drug. For the clinician, and in 
particular for the anesthesiologist providing anesthesia and post-operative pain 
management, there are to date no guidelines or recommendations that suggest any 
pharmacogenetic testing prior to administering any anesthesia-related drug. Consequently, 
it is still too early to foresee immediate implications of pharmacogenetics in general and 
pharmacogenetic diagnostic tests specifically, but one can hope that future discoveries in the 
field of genomics will soon aid anesthesiologists and other clinicians in predicting efficacy 
or toxicity for some drugs.  
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